AI assistant
Sending…
BridgeBio Pharma, Inc. — Director's Dealing 2021
Aug 26, 2021
30604_dirs_2021-08-26_d1bb9326-d89a-4ad7-9504-ff337f058678.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2021-08-17
Reporting Person: Dachille Douglas A. (Director)
More from BridgeBio Pharma, Inc.
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Feb 27